Navin M. Geria is chief scientific officer, AyurDerm Technologies LLCNavin Geria, former Pfizer Research Fellow is a cosmetic and pharmaceutical product development chemist and the chief scientific officer of AyurDerm Technologies LLC, which provides Ayurvedic, natural and cosmeceutical custom formulation development and consulting services to the spa-wellness-dermatology industries. He has launched dozens of cosmeceutical and ayurvedic anti-aging products in the market place. Geria has more than 30 years of experience in the personal care industry and was previously with Clairol, Warner-Lambert, Schick-Energizer, Bristol-Myers and Spa Dermaceuticals. He has nearly 20 US patents and has been published extensively. Geria edited the “Handbook of Skin-Aging Theories for Cosmetic Formulation Development” focus book published in April 2016 by Harry’s Cosmeticology. He is a speaker, moderator and chairman at cosmetic industry events.
ANDREW ALEXIS, MD
Andrew F. Alexis, MD, MPH is the Chair of the Department of Dermatology at Mount Sinai St. Luke’s and Mount Sinai West. He is also Associate Professor of Dermatology at the Icahn School of Medicine at Mount Sinai. As Director of the Skin of Color Center, he is actively involved in advancing patient care, research, and education pertaining to dermatologic disorders that are prevalent in ethnic skin.
Dr. Alexis received his medical degree from Columbia University College of Physicians & Surgeons and his Master of Public Health at Columbia University’s Mailman School of Public Health. He completed his dermatology residency at Weill Cornell Medical Center, followed by a fellowship in dermatopharmacology at New York University School of Medicine.
Dr. Alexis has published more than 70 articles in peer-reviewed journals including the British Journal of Dermatology, Journal of the American Academy of Dermatology, and Archives of Dermatology among others. He has co-edited two text books on dermatology for skin of color – Skin of Color A Practical Guide to Dermatologic Diagnosis and Treatment (Springer Publishing 2013) and Ethnic Dermatology: Principles and Practice (Wiley-Blackwell 2013) – and authored 10 book chapters.
Dr. Alexis has held numerous leadership positions in professional organizations including Past President of the New York Academy of Medicine Dermatology Section, Secretary/Treasurer of the Skin of Color Society and Chair of the Diversity Task Force Committee for the American Academy of Dermatology. He currently serves as President of the New York Dermatological Society, Chair of the Scientific Committee of the Skin of Color Society, and is a member of the Board of Directors of the Cicatricial Alopecia Research Foundation.
Dr. Alexis has appeared on ABC, CBS, NBC, and FOX television news programs and has been quoted in numerous leading publications, including the New York Times, Wall Street Journal, Forbes, Allure, and Essence. He is listed in Castle Connolly’s Top Doctors ™ and Super Doctors®.
NAOMI J. HALPERN
Naomi Halpern’s practice involves advising clients on a broad range of regulatory issues involving the Food and Drug Administration (FDA) with respect to pharmaceuticals (including branded, generic prescription, and over-the-counter drugs), medical devices, foods, cosmetics, and dietary supplements, as well as those involving oversight by the US Department of Agriculture (USDA) of food safety and labeling. She also advises on the laws and regulations relating to consumer products administered by the US Consumer Product Safety Commission (CPSC). Halpern is a graduate of the University of Michigan and earned her JD with honors from The George Washington University Law School.
Georg Khazaka is general manager of Courage + Khazaka electronic. He has a Master Degree in Economics and Business Administration from the University of Wuppertal, Germany. He has as well gained longstanding experience in the cosmetics industry and working within this particular sector for more than 15 years. Courage+Khazaka electronic GmbH in Cologne, Germany is the leading company for skin measurements. Besides his experience with research and development customers, he also helps to create marketing ideas for customers on a global basis. He is a member of the International Society of Biophysics and Imaging of the Skin. Maintaining a high profile at exhibitions and congresses ensures permanent control of innovative strength with his fingers on the pulse of time. He constantly draws new ideas out of numerous research cooperations and marketing projects
William Lee is a co-founder of EpigenCare, which provides epigenetic analysis via next-generation sequencing of consumer DNA in order to generate personalized skincare routines, based on a profile matching algorithm to the ingredients of popular skincare products. He also serves as VP-operations for EpiGentek where he implements company-wdie standard operating procedures. Prior to this appointment, he was sales and marketing manager, EpiGentek.
Before joining the company, Lee was VP-business development, BioCangen Inc.
He holds an MBA from Carnegie Mellon University.
Todd Maibach is president of Acaderm.
Gopinathan K. Menon obtained his MS and PhD Degrees from the University of Baroda, India ; and held a Faculty position there. In 1979, he spent an year as a Homi Bhabha Fellow and a Visiting Professor at Michigan State University where he trained in Electron Microscopy of skin. In a subsequent sebatical at the Elias lab in UCSF ( 1982-84) he started to focus on skin barrier, and in 1988 he moved to San Francisco as a full time Research Faculty in Dermatology at UCSF. From 1993 to 2017, he held various research positions in the personal care industry in the USA, including Principal Research Fellow & head, Skin Biology research at Avon Products ,and Senior Research Fellow at the International Specialty Products & Ashland,Inc. Presently he is a Fellow of the California Academy of Sciences, San Francisco.
His Honors include being awarded a Homi Bhabha Fellowship, elected as a Fellow of the California Academy of Sciences, chair of the Gordon Research Conference on Barrier Function of Mammalian Skin (2011) , and induction to the GRC Chairs’ Hall of Fame (2012) . He has been an invited speaker at several national and International meetings, and has over a hundred publications that include peer reviewed research papers, reviews and book chapters.
HOWARD MURAD, MD
Howard Murad, M.D. is recognized as a leading visionary for his scientific innovations and founder of the Inclusive Health movement, which focuses on a total body approach to youth building and overall wellness. His mission and passion is to help people unlock their potential to look younger, to feel younger and to live healthier, happier and more rewarding lives. By sharing his scientific discovery of The Science of Cellular Water™, which identifies the common denominator of aging and illness as cellular water loss, he empowers people to achieve whole-body wellness, effortless weight management and freedom from stress—the keys to living well and aging well.
A board certified dermatologist, trained pharmacist and Associate Clinical Professor of Medicine at the Geffen School of Medicine, UCLA, Dr. Murad has personally treated over 50,000 patients. In 1989 – 25 years ago — he founded Murad, Inc., as a way to share his groundbreaking skincare formulas, which were among the first to achieve significant measurable anti-aging results without surgery. Dr. Murad continues his innovative research and holds 19 patents for advances in the science of skin health.
Known as “The Father of Internal Skincare” for being an originator of the use of dietary supplements to promote skin health and as the pioneer of the use of Alpha Hydroxy Acids in topical skin care, Dr. Murad has received numerous recognitions including “The Aesthetic Visionary Award for Lifetime Achievement” from The Aesthetic Show – (an award that is now called the “Howard Murad, MD Visionary Award”). He has also been named the “Best Forward-Thinking Doctor” by Vogue magazine, a “Beauty Genius” by Elle magazine and an “Industry Visionary” by the International SPA Association. Additionally, he discovered and continuously conducts research on the impact of Cultural Stress®, the constant and pervasive form of stress due to modern day living which has been scientifically shown to have a negative impact on cellular health.
GABRIEL NISTOR, MD
Dr. Nistor is currently Chief Science Officer at AIVITA Biomedical Inc, Irvine, California. He has broad, multidisciplinary knowledge and skills in all science areas, with primary expertise in the biological and medical fields.
He is a world leader in cell biology and stem cell research and has developed many novel methods and procedures to the advancement of those fields. Dr. Nistor successfully developed a human stem cell derived treatment for acute spinal cord injuries that was approved by the FDA for clinical trials in humans, marking the first human embryonic stem cell trial ever approved in the U.S.
Most recently Dr. Nistor focused the accumulated cell biology knowledge into skin care, antiaging and rejuvenation, realizing that mitigating aging is part of the human social needs. Furthermore, the proceeds generated from the skin care products are entirely used in the AIVITA’s phase II Clinical trial for ovarian cancer.
At AIVITA Biomedical, Dr. Nistor is overseeing the activities in R&D and the manufacturing for the clinical trials in oncology. In the oncology program he uses autologous tumor antigens to train autologous- in-vitro generated dendritic cells to make a personalized autologous immunotherapy targeting solid tumors.
In the most recent research at AIVITA Biomedical, Dr. Nistor successfully harvested stem cell specific lipid modified, membrane bound cell signals from Wnt and Hedgehog families, preserved in active forms and topical deliverable. The discovery has profound implications on skin biology, demonstrating regenerative capabilities of the skin stem cell niche, including the epidermis and hair follicles. At AIVITA Biomedical he developed a first generation of products based on Wnt/Hedgehog active ingredients for skin care. Previously he demonstrated that stem cell-secreted alpha2-HS glycoprotein containing topical formulations significantly improved intrinsic and extrinsic skin aging in a 120 patient trial.
From 2006-2014 Gabriel served as Vice President, Research and Development at California Stem Cell, Inc. There he developed and patented reagent, manufacturing processes, in-process control and releasing criteria for stem cell derivates suitable for cell-replacement therapies.
Prior to joining AIVITA Biomedical, Dr. Nistor served as Vice President, Research at Caladrius Biosciences. There he created a quality-by-design environment compliant with modern cGMP practices to support the research, development and manufacturing troubleshooting of a phase III clinical trial for advanced stage melanoma using autologous tumor initiating cells and autologous dendritic cells. Gabriel’s accomplishments at Caladrius Biosciences include successfully isolating and expanding circulating tumor cells from cancer patients and identified factors that allow survival of the cells in routine blood samples. He has developed proprietary reagents and methods that enabled consistent isolation of cancer “stem” cells from bulk tumors and rapid expansion for use as antigenic sources. He has also discovered clinical predictive and efficacy biomarkers for dendritic cell based immune-therapy that could complement the current approaches based on checkpoint inhibitors.
Dr. Nistor has authored multiple patents and peer-reviewed publications in stem cells and cancer immunotherapy, and submitted and been awarded multiple grants from agencies totaling over $20 million.
MARINA I. PEREDO, MD
Dr. Peredo is an associate clinical professor of Dermatology at Mount Sinai Hospital in New York. Dr. Peredo received her medical degree from Mount Sinai School of Medicine. She completed her internal medicine internship at Columbia-Presbyterian Medical Center and her dermatology residency at New York Hospital-Cornell Medical Center.
Dr. Peredo’s expertise in advanced laser technology, laser assisted liposuction and skin rejuvenation techniques make her a national trainer for aesthetic procedures. She has appeared as a guest on national news shows, including The View, Telemundo and was featured on the British Broadcasting Company. Her editorial credits include such publications as New Beauty Magazine, Cosmopolitan, Seventeen, Good Housekeeping and Prevention Magazines. She has published in peer reviewed journals and lectures regularly at Medical Symposia, nationally and internationally.
ALEKSANDRA J. POOLE, PhD
Dr. Poole currently serves as Vice President for Research and Development at AIVITA Biomedical Inc., Irvine, California. Dr. Poole has over a decade of expertise in designing and conducting critical pre-clinical and clinical research studies for oncology, dermatology and retina stem cells products, to bring them successfully to the clinic or the market.
Dr. Poole is an internationally renowned genetic and cancer researcher. She was a part of research team that developed several breast, melanoma and ovarian cancer therapies and stem cell derived treatments for spinal cord injury and other diseases. She successfully commercialized several cellular products, cell culture medias and reagents.
With team at AIVITA, Dr. Poole developed the most relevant antiaging and rejuvenation skin care product line entirely made of stem cell derived components. These products have shown to have a profound effect on skin cell turnover, demonstrating regenerative capabilities of the skin stem cell niche, including the epidermis and hair follicles. All proceeds from skin care line are entirely used in the AIVITA’s phase II Clinical trial for ovarian cancer.
Dr. Poole is an author of numerous patents and peer-reviewed publications in stem cells and cancer biology and submitted and been awarded multiple grants from agencies totaling over $22 million.
Georgia Ravitz is a partner in the firm’s Washington, DC, office and leads the Consumer Product Safety practice, and is a senior partner in the firm’s Food & Drug (FDA), Agriculture, and Advertising practices. She focuses on food and drug law and regulatory policy governing the regulation of farm products (e.g., eggs, poultry, meat, dairy), pharmaceuticals (including prescription drugs, generic drugs and over-the-counter drugs), biologics, cosmetics, health and beauty aids, medical devices (both PMA and 510(k) products), dietary supplements, vitamin and mineral products, food, and other consumer goods. Georgia also focuses on the laws and regulations pertaining to consumer products generally, and those administered by the US Consumer Product Safety Commission (CPSC) and various state and local regulatory agencies responsible for consumer health and safety as well as the Federal Trade Commission (FTC).
LAUREN A. THAMAN
Lauren A. Thaman is associate director P&G Ventures, Procter & Gamble. Affectionately called the Chief Credentialing Officer, Lauren is responsible for strategic communications, influencer marketing and credentialing across P&G Ventures. P&G Ventures works with experts, innovators and entrepreneurs to create brands and businesses in product categories where P&G does not provide solutions today. Within this fast-learning, startup-like environment, Lauren and her team are building and experimenting with better ways to use communications to deliver the P&G Ventures goals in direct-to-consumer businesses. Lauren created the scientific communications organization for P&G over a decade ago and continues to be passionate about using communications to drive connections and deliver business results. Lauren has spent 27 years of her more than 30 year P&G career specializing in skin, hair, and scalp technology. She holds seven patents, has published in peer reviewed journals and presented at scientific and industry meetings. She holds a BS, Chemistry from Miami University and MS, Pharmaceutical Science with a concentration of Cosmetic Science from the University of Cincinnati.